-+ 0.00%
-+ 0.00%
-+ 0.00%

Lunai Bioworks completes Neurobridge IP Holdings merger, issues $20 million preferred stock

PUBT·05/01/2026 21:18:06
Listen to the news
Lunai Bioworks completes Neurobridge IP Holdings merger, issues $20 million preferred stock
  • Lunai Bioworks completed merger of Neurobridge IP Holdings into its wholly owned subsidiary Lunai Bioworks IP on May 1, 2026.
  • Transaction transferred a multi-jurisdictional patent portfolio into Lunai structure.
  • Consideration consisted of 8 shares of Series B Convertible Preferred Stock with aggregate stated value of $20 million.
  • Oncotelic received 5 Series B shares with stated value of $12.5 million.
  • Pelerin Therapeutics received 3 Series B shares with stated value of $7.5 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000653), on May 01, 2026, and is solely responsible for the information contained therein.